Navigation Links
Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union
Date:3/22/2013

LONDON, March 22, 2013 /PRNewswire/ -- Baxter International Inc. (NYSE: BAX) and Halozyme Therapeutics, Inc., (NASDAQ: HALO) today announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (EMA CHMP) has granted a Positive Opinion to Baxter for the use of HyQvia (solution for subcutaneous use) as replacement therapy for adult patients with primary and secondary immunodeficiencies. The product is a combination of human normal immunoglobulin (IGSC, 10%) and recombinant human hyaluronidase, which facilitates the dispersion and absorption of the IGSC. 

(Logo:  http://photos.prnewswire.com/prnh/20100302/LA63139LOGO)

"This recommendation supports our efforts to improve the overall quality of care for patients. This therapy, when approved by the European Commission, would offer patients the option to administer their therapy at home, in a single subcutaneous site every three to four weeks, resulting in potentially lower systemic adverse reactions compared to intravenous treatments," said Ludwig Hantson , Ph.D., president of Baxter's BioScience business. "We look forward to introducing HyQvia as a new patient-friendly therapeutic option for immunodeficient patients."

The application was based on results from a phase III, prospective, open-label, non-controlled design clinical trial, which evaluated the safety and effectiveness of HyQvia in the prevention of acute serious bacterial infections, and the pharmacokinetic parameters compared to immunoglobulin administered intravenously. The objective of the study was to infuse a 3-or 4-week dose of the therapy in a single subc
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Halozyme Confirms Baxter Has Received A Complete Response Letter For HyQ BLA
2. Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference
3. Halozyme Reports Fourth Quarter and Year End 2012 Financial Results
4. Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera
5. Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference
6. Halozyme to Host Third Quarter Financial Results Conference Call
7. Halozyme Reports Second Quarter 2012 Financial Results
8. Halozymes Ultrafast Insulin Formulations Improved Postprandial Glycemic Control in Patients Living with Type 1 Diabetes: Phase 2 Study Results Presented at ADA 2012
9. Halozyme Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
10. Halozyme Reports First Quarter 2012 Financial Results
11. Halozyme to Host First Quarter 2012 Financial Results Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015  Results from an interim analysis of ... 5g of idarucizumab enabled emergency surgery to be ... with dabigatran (Pradaxa ® dabigatran etexilate mesylate). The ... of dabigatran enabled patients to be urgently brought ... 1.7 hours between administration of idarucizumab and start ...
(Date:9/1/2015)... AMESBURY, Mass. , Sept. 1, 2015 /PRNewswire/ ... developing a next-generation infusion management system, closed on ... new investor WuXi Healthcare Ventures. Cardinal Partners, CICA, ... Partners also participated in the round. This financing ... $6B global infusion market. Leerink Partners LLC acted ...
(Date:9/1/2015)... , Sept. 1, 2015 Within ... employees, SHL Group has rapidly reached 3,000 employees ... rapid growth in the injectable drug delivery market ... A global leader in the design and ... offers innovative designs, robust manufacturing capabilities, a lean ...
Breaking Medicine Technology:New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 2New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 3New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 4New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 5New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 6New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 7New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 8New Analysis Shows Idarucizumab* Enables Rapid Initiation of Emergency Surgery in Dabigatran-Treated Patients 9Ivenix Inc. Secures $42 Million in Funding 2Ivenix Inc. Secures $42 Million in Funding 3SHL Group Reaches Major Milestone of 3000 Employees 2
... Feb. 7, 2011 ISTO Technologies, Inc. announced today ... has granted the company a key patent covering the ... issued on February 1, 2011 as Patent # US-7,879,604, ... injecting those cells into a disc nucleus for the ...
... ANAHEIM, Calif., Feb. 7, 2011 Questcor Pharmaceuticals, Inc. (Nasdaq: ... financial results for the fourth quarter and full year ended ... close of the U.S. financial markets.  The Company will host ... at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss ...
Cached Medicine Technology:ISTO Technologies Awarded Key Patent for NuQu™ Injectable Therapy for Degenerative Disc Disease 2Questcor to Report Fourth Quarter and Full Year 2010 Earnings and Conduct Conference Call on February 23, 2011 2
(Date:9/1/2015)... ... September 01, 2015 , ... ... (NAPBS®) has announced that Edge Information Management has been granted continued ... Screening Credentialing Council (BSCC). , “Achieving and maintaining this accreditation takes ...
(Date:9/1/2015)... ... 2015 , ... With former IBMers among its founding members, Inmar has known ... than 35 years ago. A pilot program begun by the company in 2014 has ... those intent on pursuing careers in these fields. The program is now open to ...
(Date:9/1/2015)... ... September 01, 2015 , ... Royal River Natural Foods, a ... followed men and women for 19 years and found that, among those who had ... multivitamins. , The report is part of the September 2015 issue of “Natural Insights ...
(Date:9/1/2015)... ... September 01, 2015 , ... The FSH Society , the ... muscular dystrophy (FSHD), will be the beneficiary of a collection of fundraising events this ... raise awareness of the FSH Society and further FSHD research. , The ...
(Date:9/1/2015)... , ... September 01, 2015 , ... SC&H Group, a ... which includes being named a “Best of the Best” firm in the U.S., as ... named the “Best of the Best” in the U.S., selected exclusively on performance in ...
Breaking Medicine News(10 mins):Health News:Edge Information Management Granted Continued NAPBS Accreditation 2Health News:Edge Information Management Granted Continued NAPBS Accreditation 3Health News:Inmar Announces Program to Fuel Student Passion for STEM – with an Unconventional Twist 2Health News:New Study Finds Multivitamins Extend Life After Stroke, Retailer Reports 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3Health News:SC&H Group Receives Multiple Honors from INSIDE Public Accounting 2
... A new study by researchers at the University of British ... , The study, published in the Journal of Public ... are three times more likely than those who don,t to ... minimum of physical activity. , Doctoral student Ugo Lachapelle and ...
... YORK, March 26 California has one of ... As more people become,uninsured due to the ... of programs that helps people without prescription coverage,save ... Hispanics about,how to access necessary medications. During "Cover ...
... The Susan G. Komen for the Cure(R) Advocacy ... (D-MA) and Kay Bailey Hutchison (R-TX) to reignite the ... 21st Century Cancer ALERT ( A ccess to ... and T reatment) Act. (Logo: ...
... March 26 Methodist Hospital in Houston has ... to settle allegations that it defrauded the federal ... resolves allegations that Methodist improperly increased charges to ... from Medicare. In addition to its standard ...
... part of government strategy to tackle issue , , ... U.S. rivers were found to be tainted with traces ... study from the U.S. Environmental Protection Agency and Baylor ... and two types of antidepressants were among the seven ...
... 2009 Two University of Rhode Island scientists have revealed ... species (ROS) -- a type of stress signal. Their findings ... human cells and may help in the design of drugs ... Professor Gongqin Sun in the URI Department of Cell and ...
Cached Medicine News:Health News:Public transit users 3 times more likely to meet fitness guidelines: UBC research 2Health News:As the Number of Unemployed Grows, Pfizer Helpful Answers and SABEResPODER Join Forces to Educate Hispanics Who Lack Health Insurance About How to Access Prescription Medicines 2Health News:As the Number of Unemployed Grows, Pfizer Helpful Answers and SABEResPODER Join Forces to Educate Hispanics Who Lack Health Insurance About How to Access Prescription Medicines 3Health News:Susan G. Komen for the Cure(R) Advocacy Alliance Applauds Senators Kennedy, Hutchison for Bipartisan Cancer Alert Act 2Health News:Houston's Methodist Hospital to Pay U.S. More Than $9 Million to Resolve Allegations of Overcharging Medicare 2Health News:Fish in U.S. Rivers Tainted With Common Medications 2Health News:URI scientists reveal mechanism that regulates cancer-causing gene 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: